4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

No Pathway Network information available for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Pathways in the 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression SuperPath

#	Name	Source	Genes
1	4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression	WikiPathways	AKT1 EIF4E EIF4EBP1 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAP3K11 MAP3K5 MAPK1 MAPK3 MKNK1 MKNK2 MTOR PBK RAF1 TSC1 (see all 17) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	MKNK1	MAPK Interacting Serine/Threonine Kinase 1	Protein Coding	1
2	TSC1	TSC Complex Subunit 1	Protein Coding	1
3	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
4	MAP2K6	Mitogen-Activated Protein Kinase Kinase 6	Protein Coding	1
5	MAP2K3	Mitogen-Activated Protein Kinase Kinase 3	Protein Coding	1
6	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	1
7	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	1
8	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	1
9	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	1
10	PBK	PDZ Binding Kinase	Protein Coding	1
11	MAP3K5	Mitogen-Activated Protein Kinase Kinase Kinase 5	Protein Coding	1
12	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	1
13	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	1
14	EIF4EBP1	Eukaryotic Translation Initiation Factor 4E Binding Protein 1	Protein Coding	1
15	EIF4E	Eukaryotic Translation Initiation Factor 4E	Protein Coding	1
16	MAP3K11	Mitogen-Activated Protein Kinase Kinase Kinase 11	Protein Coding	1
17	MKNK2	MAPK Interacting Serine/Threonine Kinase 2	Protein Coding	1

Disorders associated with 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Noonan syndrome and noonan-related syndrome	Enrichment	MAP2K1, MAP2K2, RAF1	6.13
2	Noonan syndrome 1	Enrichment	MAP2K1, MAP2K2, RAF1	5.55
3	Rasopathy	Enrichment	MAP2K1, MAP2K2, RAF1	5.38
4	Cardiofaciocutaneous syndrome 1	Enrichment	MAP2K1, MAP2K2	5.05
5	Focal cortical dysplasia, type ii	Enrichment	MTOR, TSC1	5.05
6	Cardiofaciocutaneous syndrome	Enrichment	MAP2K1, MAP2K2	5.05
7	Isolated focal cortical dysplasia type ii	Enrichment	MTOR, TSC1	5.05
8	Proteus syndrome	Enrichment	AKT1	2.90
9	Noonan syndrome 5	Enrichment	RAF1	2.90
10	Melorheostosis, isolated	Enrichment	MAP2K1	2.90
11	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	2.90
12	Cardiofaciocutaneous syndrome 3	Enrichment	MAP2K1	2.90
13	Noonan syndrome 13	Enrichment	MAPK1	2.90
14	Autism 19	Enrichment	EIF4E	2.90
15	Melorheostosis	Enrichment	MAP2K1	2.90
16	Leopard syndrome 2	Enrichment	RAF1	2.90
17	Cardiofaciocutaneous syndrome 4	Enrichment	MAP2K2	2.90
18	Cowden syndrome 6	Enrichment	AKT1	2.90
19	Trigonitis	Enrichment	RAF1	2.90
20	Lymphangioleiomyomatosis	Enrichment	TSC1	2.60
21	Cebalid syndrome	Enrichment	MTOR	2.60
22	Smith-kingsmore syndrome	Enrichment	MTOR	2.60
23	Tafro syndrome	Enrichment	MAP2K2	2.60
24	Tuberous sclerosis 1	Enrichment	TSC1	2.43
25	Langerhans cell histiocytosis	Enrichment	MAP2K1	2.43
26	Hamartoma	Enrichment	TSC1	2.43
27	Neurofibromatosis-noonan syndrome	Enrichment	MAP2K2	2.30
28	Chromosome 22q11.2 deletion syndrome, distal	Enrichment	MAPK1	2.30
29	Tuberous sclerosis	Enrichment	TSC1	2.30
30	Noonan syndrome with multiple lentigines	Enrichment	RAF1	2.30
31	Hemimegalencephaly	Enrichment	MTOR	2.20
32	Keratoconus	Enrichment	TSC1	2.13
33	Breast adenocarcinoma	Enrichment	AKT1	2.13
34	Capillary malformation-arteriovenous malformation 1	Enrichment	MAP2K1	2.06
35	Renal cell carcinoma, papillary, 1	Enrichment	MTOR	2.06
36	Noonan syndrome 3	Enrichment	RAF1	2.06
37	Pilomyxoid astrocytoma	Enrichment	RAF1	2.06
38	Overgrowth syndrome	Enrichment	MTOR	2.06
39	Melanocytic nevus syndrome, congenital	Enrichment	RAF1	2.00
40	Arteriovenous malformation	Enrichment	MAP2K1	1.95
41	Adult hepatocellular carcinoma	Enrichment	TSC1	1.95
42	Cowden syndrome	Enrichment	AKT1	1.95
43	Myopathy, x-linked, with excessive autophagy	Enrichment	MAP2K1	1.90
44	Lung non-small cell carcinoma	Enrichment	MAP2K1	1.86
45	Specific learning disability	Enrichment	MAPK1	1.86
46	Meningioma	Enrichment	AKT1	1.83
47	Renal cell carcinoma, nonpapillary	Enrichment	MTOR	1.73
48	Kidney disease	Enrichment	TSC1	1.73
49	Rare genetic intellectual disability	Enrichment	MTOR	1.73
50	Heart, malformation of	Enrichment	MAPK1	1.65
51	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	1.53
52	Bladder cancer	Enrichment	TSC1	1.45
53	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	1.39
54	Left ventricular noncompaction	Enrichment	RAF1	1.37
55	Hereditary breast carcinoma	Enrichment	AKT1	1.27
56	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	1.19
57	Breast cancer	Enrichment	AKT1	1.05
58	Dilated cardiomyopathy	Enrichment	RAF1	1.02
59	Colorectal cancer	Enrichment	AKT1	0.98
60	Ovarian cancer	Enrichment	AKT1	0.92
61	Autism spectrum disorder	Enrichment	MAP2K1	0.89
62	Microcephaly	Enrichment	MAPK1	0.84
63	Inherited cancer-predisposing syndrome	Enrichment	TSC1	0.81

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Pathway Network for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Member Pathways for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Pathways in the 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression SuperPath

Associated Genes for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Associated Disorders for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Disorders associated with 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression SuperPath

STRING Interaction Network for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression

Sources for 4-hydroxytamoxifen, dexamethasone, and retinoic acids regulation of p27 expression